Holla Vijaykumar R, Mann Jason R, Shi Qiong, DuBois Raymond N
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-6838, USA.
J Biol Chem. 2006 Feb 3;281(5):2676-82. doi: 10.1074/jbc.M507752200. Epub 2005 Nov 17.
Many lines of research implicate cyclooxygenase 2-derived prostaglandins in tumor growth and metastasis. More specifically, we have shown that prostaglandin E2 (PGE2) promotes cell proliferation and invasion through transactivation of the epidermal growth factor receptor, initiates immune evasion through induction of decay accelerating factor, and transactivates peroxisome proliferator-activated receptor delta, leading to increased polyp size and multiplicity. We continue to identify novel PGE2 target genes in colorectal carcinoma cells and report here that an immediate early gene, nuclear factor NR4A2 (Nurr1), is induced by PGE2 that in turn regulates cell death. Originally described as a critical dopaminergic neuron growth factor receptor, NR4A2 expression is rapidly but transiently induced by PGE2 in a cAMP/protein kinase A-dependent manner. NR4A2 binds to the cognate NBRE response element and enhances transcription of a reporter construct in colorectal carcinoma cells. Furthermore, NR4A2 expression is elevated in Apc-/+ mouse adenomas and its levels were further increased following PGE2 treatment. Human colorectal cancers relative to matched normal mucosa showed increased NR4A2 expression. Although not previously described in epithelial tissues, NR4A2 protein localizes to proliferating crypts of Apc-/+ mouse intestine. Finally, functional studies reveal that PGE2-mediated protection from apoptosis is completely inhibited by a dominant-negative NR4A2 construct. Building on previous reports from our group on the peroxisome proliferator-activated receptor family of nuclear receptors, these most recent data suggest that NR4A2, a member of another family of nuclear receptors can stimulate progression of colorectal cancer downstream from cyclooxygenase 2-derived PGE2.
许多研究方向都表明,环氧化酶2衍生的前列腺素与肿瘤生长和转移有关。更具体地说,我们已经证明,前列腺素E2(PGE2)通过表皮生长因子受体的反式激活促进细胞增殖和侵袭,通过诱导衰变加速因子引发免疫逃逸,并反式激活过氧化物酶体增殖物激活受体δ,导致息肉大小增加和数量增多。我们继续在结肠癌细胞中鉴定新的PGE2靶基因,并在此报告,一种即早基因——核因子NR4A2(Nurr1),由PGE2诱导,进而调节细胞死亡。NR4A2最初被描述为一种关键的多巴胺能神经元生长因子受体,其表达在PGE2的作用下以cAMP/蛋白激酶A依赖的方式迅速但短暂地被诱导。NR4A2与同源的NBRE反应元件结合,并增强结肠癌细胞中报告基因构建体的转录。此外,在Apc-/+小鼠腺瘤中NR4A2表达升高,PGE2处理后其水平进一步增加。与匹配的正常黏膜相比,人类结直肠癌中NR4A2表达增加。尽管之前未在上皮组织中描述过,但NR4A2蛋白定位于Apc-/+小鼠肠道的增殖隐窝。最后,功能研究表明,PGE2介导的抗凋亡作用被显性负性NR4A2构建体完全抑制。基于我们小组之前关于过氧化物酶体增殖物激活受体核受体家族的报告,这些最新数据表明,核受体的另一个家族成员NR4A2可以在环氧化酶2衍生的PGE2下游刺激结直肠癌的进展。